TY - JOUR
T1 - Human heterochromatin protein 1 Isoforms regulate androgen receptor signaling in prostate cancer
AU - Itsumi, Momoe
AU - Shiota, Masaki
AU - Yokomizo, Akira
AU - Kashiwagi, Eiji
AU - Takeuchi, Ario
AU - Tatsugami, Katsunori
AU - Inokuchi, Junichi
AU - Song, Yoohyun
AU - Uchiumi, Takeshi
AU - Naito, Seiji
PY - 2013/3/27
Y1 - 2013/3/27
N2 - Androgen receptor (AR) signaling is critical for the tumorigenesis and development of prostate cancer, as well as the progression to castration-resistant prostate cancer. We previously showed that the heterochromatin protein 1 (HP1) b isoform plays a critical role in transactivation of AR signaling as an AR coactivator that promotes prostate cancer cell proliferation. However, the roles of other HP1 isoforms, HP1a and HP1g, in AR expression and prostate cancer remain unclear. Here, we found that knockdown of HP1g, but not HP1a, reduced AR expression and cell proliferation by inducing cell cycle arrest at G1 phase in LNCaP cells. Conversely, overexpression of full-length HP1a and its C-terminal deletion mutant increased AR expression and cell growth, whereas overexpression of HP1g had no effect. Similarly, HP1a overexpression promoted 22Rv1 cell growth, whereas HP1g knockdown reduced the proliferation of CxR cells, a castration-resistant LNCaP derivative. Taken together, HP1 isoforms distinctly augment AR signaling and cell growth in prostate cancer. Therefore, silencing of HP1b and HP1g may be a promising therapeutic strategy for treatment of prostate cancer.
AB - Androgen receptor (AR) signaling is critical for the tumorigenesis and development of prostate cancer, as well as the progression to castration-resistant prostate cancer. We previously showed that the heterochromatin protein 1 (HP1) b isoform plays a critical role in transactivation of AR signaling as an AR coactivator that promotes prostate cancer cell proliferation. However, the roles of other HP1 isoforms, HP1a and HP1g, in AR expression and prostate cancer remain unclear. Here, we found that knockdown of HP1g, but not HP1a, reduced AR expression and cell proliferation by inducing cell cycle arrest at G1 phase in LNCaP cells. Conversely, overexpression of full-length HP1a and its C-terminal deletion mutant increased AR expression and cell growth, whereas overexpression of HP1g had no effect. Similarly, HP1a overexpression promoted 22Rv1 cell growth, whereas HP1g knockdown reduced the proliferation of CxR cells, a castration-resistant LNCaP derivative. Taken together, HP1 isoforms distinctly augment AR signaling and cell growth in prostate cancer. Therefore, silencing of HP1b and HP1g may be a promising therapeutic strategy for treatment of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=84876710388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876710388&partnerID=8YFLogxK
U2 - 10.1530/JME-13-0024
DO - 10.1530/JME-13-0024
M3 - Article
C2 - 23536649
AN - SCOPUS:84876710388
SN - 0952-5041
VL - 50
SP - 401
EP - 409
JO - Journal of Molecular Endocrinology
JF - Journal of Molecular Endocrinology
IS - 3
ER -